Escherichia coli Nissle 1917 as adjuvant therapy in patients with chronic bacterial prostatitis: a non-blinded, randomized, controlled trial
Purpose To evaluate the efficacy and safety of Escherichia coli Nissle 1917 (EcN) in association with levofloxacin in patients with chronic bacterial prostatitis (CBP). Methods Patients with CBP referred to our clinic from September 2017 to July 2019 were enrolled. At baseline, the symptomatology wa...
Saved in:
Published in | World journal of urology Vol. 39; no. 12; pp. 4373 - 4379 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.12.2021
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Purpose
To evaluate the efficacy and safety of
Escherichia coli
Nissle 1917 (EcN) in association with levofloxacin in patients with chronic bacterial prostatitis (CBP).
Methods
Patients with CBP referred to our clinic from September 2017 to July 2019 were enrolled. At baseline, the symptomatology was assessed with the NIH-Chronic Prostatitis Symptom Index (NIH-CPSI), while the Meares–Stamey test was used to diagnose the infection. Patients were randomized (1:1) in two groups (A and B). All subjects underwent oral administration of Levoxacin® 500 mg once daily for 4 weeks. Only the patients in Group B underwent oral administration of EcN® 320 mg, twice daily for 4 weeks and then once daily for 8 weeks. After 3 months, each patient repeated the NIH-CPSI questionnaire, while the Meares–Stamey test was repeated at 3 and 6 months in patients who reported persistent symptoms. All adverse events (AEs) were recorded.
Results
A total of 110 patients were enrolled. After 3 months patients in Group B reported a significantly lower NIH-CPSI score (5.85 ± 3.07 vs. 7.64 ± 3.86;
p
= 0.009) and biological recurrences rate (9.8 vs. 26.9%;
p
= 0.043). At 6 months the biological recurrences rate was significantly lower in Group B (8.7 vs. 28.9%;
p
= 0.038). Only three patients in Group A and six in Group B (
p
= 0.25) complained mild AEs.
Conclusions
Combination therapy with EcN and levofloxacin allows a better control of symptoms and biological recurrences in patients with CBP, without worsening the safety of the treatment. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-News-1 ObjectType-Feature-3 content type line 23 |
ISSN: | 0724-4983 1433-8726 |
DOI: | 10.1007/s00345-021-03773-8 |